All News
Filter News
Found 808,966 articles
-
Epic Bio to Participate in the 6th International Conference on Epigenetics and Bioengineering
10/25/2022
Epic Bio today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022.
-
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray
10/25/2022
Milestone Pharmaceuticals Inc. today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually.
-
NuVasive Announces Conference Call and Webcast of Third Quarter 2022 Results
10/25/2022
NuVasive, Inc. announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close.
-
PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting
10/25/2022
Prelude Corporation today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior risk and RT benefit prediction compared to common clinicopathologic features.
-
iSpecimen to Report Third Quarter 2022 Results on November 8, 2022
10/25/2022
iSpecimen Inc. today announced that it will report its financial results for the third quarter ended September 30, 2022, before the markets open on Tuesday, November 8, 2022.
-
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022
10/25/2022
Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022.
-
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
10/25/2022
Can-Fite BioPharma Ltd. announced today that a poster entitled “Complete Response Induced by Namodenoson, an A3 Adenosine Receptor Agonist, in a Patient with Advanced Hepatocellular Carcinoma”
-
CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting
10/25/2022
CareDx, Inc. today announced its leading presence as a Diamond Level sponsor at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.
-
Orthofix Medical Schedules Third Quarter Earnings Release and Conference Call for November 3, 2022
10/25/2022
Orthofix Medical Inc. today announced that it will release its third quarter 2022 financial results before market open on Thursday, November 3, 2022.
-
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
10/25/2022
Aclarion, Inc. will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles.
-
Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
10/25/2022
Seelos Therapeutics, Inc. today announced dosing of the first patient in a registrational phase II/III study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (SCA3, also known as Machado-Joseph disease) and also announced that it will participate in the International Congress for Ataxia Research (ICAR) in Dallas, Texas November 1st – 4th, 2022.
-
INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
10/25/2022
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2022 financial results will be released after the market close on November 8, 2022 .
-
Surgalign Schedules Third Quarter 2022 Earnings Release for November 2, 2022
10/25/2022
Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its third quarter ended September 30, 2022 after the close of trading on November 2, 2022.
-
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
10/25/2022
Agenus today announced the Company will release its second quarter 2022 financial results before the market opens on Tuesday, November 8, 2022.
-
STERIS to Host a Conference Call for Fiscal 2023 Second Quarter Financial Results on November 10, 2022
10/25/2022
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 second quarter financial results at 10:00 a.m. ET on November 10, 2022.
-
Silk Road Medical to Report Third Quarter 2022 Financial Results on November 8, 2022
10/25/2022
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8th, 2022.
-
JUNO DIAGNOSTICS ANNOUNCES PRESENTATION AT CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE
10/25/2022
Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participation in the Credit Suisse 31st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA.
-
Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference
10/25/2022
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of its management team are scheduled to participate in Credit Suisse’s 31st Annual Healthcare Conference on Tuesday, November 8, 2022.
-
Arcutis to Report Third Quarter Financial Results
10/25/2022
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m. ET on Tuesday, November 8, 2022, to report its third quarter financial results.
-
Masimo to Report Third Quarter 2022 Financial Results after Market Close on Tuesday, November 8
10/25/2022
Masimo (NASDAQ: MASI) will release third quarter 2022 financial results for the period ended October 1, 2022, after the market closes on Tuesday, November 8, 2022.